drugset / Trial / NCT05580250

A Study of LY3526318 in Healthy Male Japanese Participants

NCT05580250

Phase 1 Withdrawn Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science

Summary

This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to: * Assess how safe and well tolerated LY3526318 is when given by mouth. * Measure how LY3526318 affects the kidney and the liver. The study will be conducted in three parts (Part A, Part B, Part C). Participants may only enroll in one part. After screening, the study will last from one to two weeks, depending on part.

Timeline

Start
2022-11-22
Primary completion
2022-12-08
Completion
2022-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3526318 Unknown Oral
Subject Metformin Small molecule Oral
Subject Simvastatin Small molecule Oral
Background Iohexol Diagnostic / imaging agent Intravenous

Indications

No indication recorded.